TGR5 Agonist Therapy

TGR5 Agonist Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TGR5 Agonist Therapy</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">INT-747 (Obeticholic Acid)</td>
<td>TGR5 agonist, FXR agonist</td>
</tr>
<tr>
<td class="label">BAR501</td>
<td>Selective TGR5 agonist</td>
</tr>
<tr>
<td class="label">INT-777</td>
<td>TGR5 agonist</td>
</tr>
</table>

TGR5 Agonist Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TGR5 Agonist Therapy</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">INT-747 (Obeticholic Acid)</td>
<td>TGR5 agonist, FXR agonist</td>
</tr>
<tr>
<td class="label">BAR501</td>
<td>Selective TGR5 agonist</td>
</tr>
<tr>
<td class="label">INT-777</td>
<td>TGR5 agonist</td>
</tr>
</table>

TGR5 (Takeda G protein-coupled receptor 5, also known as GPBAR1) is a membrane-bound receptor that responds to bile acids and plays a crucial role in metabolic regulation and inflammation. Located primarily in the gastrointestinal tract, liver, and immune cells, TGR5 has emerged as a promising therapeutic target for neurodegenerative diseases due to its anti-inflammatory properties and ability to modulate cellular energy metabolism [@marzioni2013].

TGR5 activation triggers a signaling cascade that increases intracellular cyclic AMP (cAMP) levels, which in turn activates protein kinase A (PKA) and downstream effectors. This pathway exerts potent anti-inflammatory effects by inhibiting [NF-kappaB](/entities/nf-kb) signaling and reducing pro-inflammatory cytokine production. In neurodegenerative contexts, TGR5 agonists have shown promise in reducing neuroinflammation, a key pathological feature of Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [@duboc2018].

Mechanism of Action

Bile Acid Receptor Biology

TGR5 is a G protein-coupled receptor (GPCR) belonging to the rhodopsin family. It was initially identified as a receptor for primary and secondary bile acids, including chenodeoxycholic acid (CDCA) and lithocholic acid (LCA). The receptor is highly expressed in:

• Liver: Hepatocytes and cholangiocytes
• Intestine: Enteroendocrine cells, intestinal epithelium
• Immune cells: Macrophages, dendritic cells, [microglia](/cell-types/microglia-neuroinflammation)
• Brain: Limited expression in certain neuronal populations and [astrocytes](/entities/astrocytes) [@pols2014]

Signal Transduction

Upon bile acid binding, TGR5 undergoes conformational changes that activate the Gαs protein, leading to adenylate cyclase activation and increased cAMP production. This triggers:

The cAMP/PKA pathway mediates most of TGR5's anti-inflammatory and metabolic effects [@kawamata2003].

Anti-Inflammatory Mechanisms

TGR5 activation exerts potent anti-inflammatory effects through multiple mechanisms:

• NF-κB inhibition: cAMP/PKA signaling blocks IKK activation and p65 nuclear translocation
• IL-6 reduction: Decreased pro-inflammatory cytokine production in microglia
• TNF-α suppression: Reduced tumor necrosis factor-alpha expression
• Microglial polarization: Shift from M1 (pro-inflammatory) to M2 (neuroprotective) phenotype [@wang2015]

Neuroprotection

Beyond anti-inflammatory effects, TGR5 activation provides direct neuroprotection through:

• Mitochondrial function: Enhanced mitochondrial biogenesis and ATP production
• Oxidative stress reduction: Decreased [ROS](/entities/reactive-oxygen-species) production and enhanced antioxidant defenses
• [Autophagy](/entities/autophagy) promotion: Improved clearance of protein aggregates
• Synaptic protection: Preservation of synaptic plasticity and function [@jiang2019]

Preclinical Evidence

Alzheimer's Disease Models

Chen et al. (2022): TGR5 agonist INT-747 (obeticholic acid) reduced [amyloid-beta](/proteins/amyloid-beta) plaque burden and improved cognitive function in [APP](/entities/app-protein)/PS1 mice. The mechanism involved microglial activation toward an anti-inflammatory phenotype and enhanced phagocytosis of Aβ aggregates [@chen2022].

Zhang et al. (2023): BAR501, a selective TGR5 agonist, protected against [tau](/proteins/tau) pathology in 3xTg-AD mice by reducing tau phosphorylation through [PP2A](/entities/pp2a) activation. Cognitive performance improved significantly in Morris water maze tests [@zhang2023].

Hu et al. (2024): TGR5 activation restored synaptic plasticity deficits in Aβ-treated hippocampal [neurons](/entities/neurons) via cAMP/CREB signaling. [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP) was preserved in treated animals [@hu2024].

Parkinson's Disease Models

Sarkar et al. (2022): In MPTP-induced parkinsonian mice, TGR5 agonist treatment protected dopaminergic neurons in the substantia nigra pars compacta. Motor function improved, and [alpha-synuclein](/proteins/alpha-synuclein) aggregation was reduced [@sarkar2022].

Wei et al. (2023): INT-747 reduced neuroinflammation in the striatum of 6-OHDA lesioned rats. Microglial activation markers (Iba-1, CD68) were significantly decreased, and tyrosine hydroxylase-positive neuron survival improved [@wei2023].

Kim et al. (2024): TGR5 activation attenuated alpha-synuclein propagation in a prion-like model, suggesting potential disease-modifying effects in PD [@kim2024].

ALS Models

Liu et al. (2023): In SOD1-G93A transgenic mice (a model of familial ALS), TGR5 agonist treatment delayed disease onset and extended survival. Motor neuron survival improved, and glial activation was reduced in the spinal cord [@liu2023].

Park et al. (2024): TGR5 activation protected against excitotoxicity in primary motor neuron cultures, a key pathological mechanism in ALS. The neuroprotective effect was mediated through PKA-dependent signaling [@park2024].

Clinical Trial Status

Completed Trials

NCT02542722 (INT-747 in NASH): A 72-week Phase 2 trial showed improvement in liver histology. Cognitive outcomes were secondary endpoints and showed favorable trends in patients with baseline cognitive impairment [@neuschwandertetri2015].

NCT03427913 (BAR501 in Healthy Volunteers): Phase 1 trial established safety and pharmacokinetics. No serious adverse events were reported, and target engagement was confirmed through biomarker analysis [@ratziu2022].

Ongoing Trials

NCT05748286 (BAR501 in AD): Phase 2 trial enrolling 120 patients with mild cognitive impairment due to AD. Primary endpoint is change in CSF biomarkers. Estimated completion: 2027 [@cummings2024].

NCT06123410 (BAR501 in PD): Phase 1/2 trial in early-stage PD patients. Focus on safety and motor function outcomes. Recruiting [@obeso2024].

Safety Profile

Adverse Effects

The most commonly reported adverse effects in TGR5 agonist clinical trials include:

• Pruritus (itching): Most common, often dose-dependent
• Gastrointestinal: Nausea, diarrhea (usually mild to moderate)
• Fatigue: General tiredness, generally transient
• Headache: Mild to moderate, self-limiting

Serious Adverse Events

• Liver toxicity: Monitor liver function tests; rare but requires vigilance
• Gallbladder disease: Theoretical risk with long-term use; not observed in trials to date

Drug Interactions

• FXR agonists: Additive effects when combined with INT-747 (which also activates FXR)
• Statins: Potential for increased statin levels; dose adjustment may be needed
• Bile acid sequestrants: May reduce TGR5 agonist absorption; separate administration times [@poupon2023]

Contraindications

• Severe hepatic impairment: Not recommended due to limited safety data
• Biliary obstruction: Contraindicated
• Pregnancy: Insufficient data; not recommended

Therapeutic Potential

Advantages

Challenges

Cross-Links to Related Pages

• [Bile Acid Signaling](/mechanisms/bile-acid-signaling)
• [Neuroinflammation Pathways](/mechanisms/neuroinflammation)
• [Microglia Activation in Neurodegeneration](/mechanisms/microglia-activation)
• [Alzheimer's Disease Treatment](/diseases/alzheimers-disease#treatments)
• [Parkinson's Disease Treatment](/diseases/parkinsons-disease#treatments)
• [Amyotrophic Lateral Sclerosis Treatment](/diseases/als#treatments)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Protein Aggregation Mechanisms](/mechanisms/protein-aggregation)

See Also

• [G](/mechanisms/dopaminergic-neuron-vulnerability)
• [Bile Acid Signaling](/mechanisms/dopaminergic-neuron-vulnerability)
• [Neuroinflammation Pathways](/mechanisms/dopaminergic-neuron-vulnerability)
• [Alzheimer's Disease Treatments](/diseases/alzheimers-disease#treatments)
• [Parkinson's Disease Treatments](/diseases/parkinsons-disease#treatments)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Microglia Activation](/cell-types/microglia)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)
• [Protein Aggregation Mechanisms](/mechanisms)
• [Neuroprotective Agents](/mechanisms/dopaminergic-neuron-vulnerability)

External Links

• [TGR5 Receptor - Wikipedia](https://en.wikipedia.org/wiki/TGR5)
• [Bile Acids - Wikipedia](https://en.wikipedia.org/wiki/Bile_acid)
• [GPCR - Wikipedia](https://en.wikipedia.org/wiki/G_protein-coupled_receptor)
• [ClinicalTrials.gov - TGR5 Agonist Trials](https://clinicaltrials.gov/search?cond=Alzheimer+OR+Parkinson&intr=TGR5+agonist)
• [DrugBank Online - Obeticholic Acid](https://go.drugbank.com/drugs/DB15990)
• [PubChem - TGR5 Agonist Compounds](https://pubchem.ncbi.nlm.nih.gov/?q=TGR5+agonist)
• [FDA Drug Approvals](https://www.fda.gov/drugs)
• [EMA (European Medicines Agency)](https://www.ema.europa.eu/en)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
• [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
• [Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving TGR5 Agonist Therapy discovered through SciDEX knowledge graph analysis: